PMID- 38036157
OWN - NLM
STAT- MEDLINE
DCOM- 20240108
LR  - 20240108
IS  - 1879-0461 (Electronic)
IS  - 1040-8428 (Linking)
VI  - 193
DP  - 2024 Jan
TI  - Somatostatin receptor2 (SSTR2) expression, prognostic implications, modifications 
      and potential therapeutic strategies associates with head and neck squamous cell 
      carcinomas.
PG  - 104223
LID - S1040-8428(23)00311-6 [pii]
LID - 10.1016/j.critrevonc.2023.104223 [doi]
AB  - Head and neck squamous cell carcinomas (HNSCC) constitute a heterogeneous cluster 
      of tumors celebrated for their predisposition to metastasize and exhibit local 
      recurrence. Recent explorations have illuminated the intricate involvement of 
      Somatostatin Receptor 2 (SSTR2), a growth-regulatory receptor traditionally 
      classified as a tumor suppressor, yet concurrently implicated in bolstering 
      specific tumor phenotypes. Advances in the realm of SSTR2 investigation within 
      HNSCC, with a specific spotlight on laryngeal squamous cell carcinomas (LSCC), 
      tongue squamous cell carcinomas (TSCC), and nasopharyngeal carcinomas (NPC), have 
      been established. This study aims to provide a comprehensive overview of SSTR2 
      expression patterns, prognostic implications, distinctive signaling pathways, 
      epigenetic modifications, and potential therapeutic strategies associated with 
      SSTR2 in HNSCC.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Fan, Songqing
AU  - Fan S
AD  - Department of Pathology, The Second Xiangya Hospital, Central South University, 
      Changsha, Hunan, China; Hunan Clinical Medical Research Center for Cancer 
      Pathogenic Genes Testing and Diagnosis, Changsha, Hunan 410011, China.
FAU - Zheng, Hongmei
AU  - Zheng H
AD  - Department of Pathology, The Second Xiangya Hospital, Central South University, 
      Changsha, Hunan, China; Hunan Clinical Medical Research Center for Cancer 
      Pathogenic Genes Testing and Diagnosis, Changsha, Hunan 410011, China.
FAU - Zhan, Yuting
AU  - Zhan Y
AD  - Department of Pathology, The Second Xiangya Hospital, Central South University, 
      Changsha, Hunan, China; Hunan Clinical Medical Research Center for Cancer 
      Pathogenic Genes Testing and Diagnosis, Changsha, Hunan 410011, China.
FAU - Luo, Jiadi
AU  - Luo J
AD  - Department of Pathology, The Second Xiangya Hospital, Central South University, 
      Changsha, Hunan, China; Hunan Clinical Medical Research Center for Cancer 
      Pathogenic Genes Testing and Diagnosis, Changsha, Hunan 410011, China.
FAU - Zang, Hongjing
AU  - Zang H
AD  - Department of Pathology, The Second Xiangya Hospital, Central South University, 
      Changsha, Hunan, China; Hunan Clinical Medical Research Center for Cancer 
      Pathogenic Genes Testing and Diagnosis, Changsha, Hunan 410011, China.
FAU - Wang, Huilin
AU  - Wang H
AD  - Department of Pathology, The Second Xiangya Hospital, Central South University, 
      Changsha, Hunan, China; Hunan Clinical Medical Research Center for Cancer 
      Pathogenic Genes Testing and Diagnosis, Changsha, Hunan 410011, China.
FAU - Wang, Weiyuan
AU  - Wang W
AD  - Department of Pathology, Xiangya Hospital, Central South University, Changsha, 
      Hunan, China.
FAU - Xu, Yue
AU  - Xu Y
AD  - Department of Pathology, The Second Xiangya Hospital, Central South University, 
      Changsha, Hunan, China; Hunan Clinical Medical Research Center for Cancer 
      Pathogenic Genes Testing and Diagnosis, Changsha, Hunan 410011, China. Electronic 
      address: 218211011@csu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231129
PL  - Netherlands
TA  - Crit Rev Oncol Hematol
JT  - Critical reviews in oncology/hematology
JID - 8916049
RN  - 0 (Biomarkers, Tumor)
RN  - 51110-01-1 (Somatostatin)
SB  - IM
MH  - Humans
MH  - Squamous Cell Carcinoma of Head and Neck/diagnosis/genetics/therapy
MH  - Prognosis
MH  - *Head and Neck Neoplasms/diagnosis/genetics/therapy
MH  - Biomarkers, Tumor/genetics
MH  - *Carcinoma, Squamous Cell/diagnosis/genetics/therapy
MH  - Somatostatin
OTO - NOTNLM
OT  - Head and neck squamous cell carcinomas
OT  - Methylation
OT  - Somatostatin Receptor 2
OT  - Therapy
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationship that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/12/01 00:43
MHDA- 2024/01/08 06:43
CRDT- 2023/11/30 21:56
PHST- 2023/09/03 00:00 [received]
PHST- 2023/11/13 00:00 [revised]
PHST- 2023/11/24 00:00 [accepted]
PHST- 2024/01/08 06:43 [medline]
PHST- 2023/12/01 00:43 [pubmed]
PHST- 2023/11/30 21:56 [entrez]
AID - S1040-8428(23)00311-6 [pii]
AID - 10.1016/j.critrevonc.2023.104223 [doi]
PST - ppublish
SO  - Crit Rev Oncol Hematol. 2024 Jan;193:104223. doi: 
      10.1016/j.critrevonc.2023.104223. Epub 2023 Nov 29.